ARTICLE | Emerging Company Profile
Avalon-incubated biotech now has $161M to advance what could be the first covalent, irreversible protein drugs, starting in oncology
By Paul Bonanos, Director of Biopharma Intelligence
April 30, 2024 11:56 AM UTC
Incubated by Avalon Ventures, three-and-a-half-year-old Enlaza is moving toward the clinic with $161 million in funding and a platform with which it could create the first covalent biologic drugs.
With technologies in-licensed from the University of California San Francisco and the Scripps Research Institute, San Diego-based Enlaza Therapeutics Inc. is attempting to develop efficacious biologics that have longer occupancy, durable effects, dosing advantages, and reduced systemic exposure, compared with existing non-covalent biologics…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652257/enlaza-creating-covalent-biologics-using-engineered-amino-acids